Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A Five-Year Follow-Up Investigation

被引：0
|
作者：
Reinhard Angermann
Alexander Franchi
Victoria Stöckl
Julia Rettenwander
Tanja Rettenwander
David Goldin
Martin Stattin
Martina T. Kralinger
Claus Zehetner
机构：
[1] Medical University Innsbruck,Department of Ophthalmology
[2] Paracelsus Medical University Salzburg,Department of Ophthalmology
[3] Clinic Landstraße,Department of Ophthalmology
[4] Vienna Healthcare Group,undefined
[5] Karl Landsteiner Institute for Retinal Research and Imaging,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Anti-VEGF; Compliance; Macular degeneration; Nonpersistence; Vision loss;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：559 / 571
页数：12
相关论文
共 50 条
  • [21] INTRAVITREAL AFLIBERCEPT FOR TREATMENT-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Chang, Andrew A.
    Li, Haitao
    Broadhead, Geoffrey K.
    Hong, Thomas
    Schlub, Timothy E.
    Wijeyakumar, Wijeyanthy
    Zhu, Meidong
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 41 : 52 - 52
  • [22] TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Barthelmes, Daniel
    Vuong Nguyen
    Daien, Vincent
    Campain, Anna
    Walton, Richard
    Guymer, Robyn
    Morlet, Nigel
    Hunyor, Alex P.
    Essex, Rohan W.
    Arnold, Jennifer J.
    Gillies, Mark C.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (01): : 20 - 28
  • [23] Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab
    Momenaei, Bita
    Yonekawa, Yoshihiro
    Abril, Paige
    Mccullough, Rachel
    Abbey, Ashkan M.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2025,
  • [24] Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration Patients: 3-Year Outcomes
    Wijeyakumar, Wijeyanthy
    Zhu, Meidong
    Chang, Andrew Alexander
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [25] First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration
    Aljundi, Wissam
    Daas, Loay
    Suffo, Shady
    Seitz, Berthold
    Abdin, Alaa Din
    PHARMACEUTICS, 2024, 16 (04)
  • [26] Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
    Kim, Jae Hui
    Kim, Jong Woo
    Kim, Chul Gu
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2021, 37 (09) : 525 - 533
  • [27] Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
    Gharbiya, Magda
    Iannetti, Ludovico
    Parisi, Francesco
    De Vico, Umberto
    Mungo, Maria Laura
    Marenco, Marco
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [28] Limited Treatment Response during Follow-up after Switching to Aflibercept in Neovascular Age-related Macular Degeneration
    Choe, Gon Soo
    Kim, Jong Woo
    Kim, Chul Gu
    Kim, Jae Hui
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2021, 62 (09): : 1218 - 1226
  • [29] Outcomes of Eyes Lost to Follow-Up with Neovascular Age Related Macular Degeneration Receiving Intravitreal Anti-VEGF
    Soares, Rebecca Russ
    Mellen, Phoebe L.
    Garrigan, Hannah
    Obeid, Anthony
    Wibbelsman, Turner D.
    Borkar, Durga S.
    Ho, Allen C.
    Hsu, Jason
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [30] Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept
    Yildiz, Dilan
    Cakir, Akin
    Erden, Burak
    Bolukbasi, Selim
    Erdenoz, Serkan
    Elcioglu, Mustafa Nuri
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2021, 13
12345